Revised response criteria for malignant lymphoma - PubMed (original) (raw)
Practice Guideline
. 2007 Feb 10;25(5):579-86.
doi: 10.1200/JCO.2006.09.2403. Epub 2007 Jan 22.
Beate Pfistner, Malik E Juweid, Randy D Gascoyne, Lena Specht, Sandra J Horning, Bertrand Coiffier, Richard I Fisher, Anton Hagenbeek, Emanuele Zucca, Steven T Rosen, Sigrid Stroobants, T Andrew Lister, Richard T Hoppe, Martin Dreyling, Kensei Tobinai, Julie M Vose, Joseph M Connors, Massimo Federico, Volker Diehl; International Harmonization Project on Lymphoma
Affiliations
- PMID: 17242396
- DOI: 10.1200/JCO.2006.09.2403
Practice Guideline
Revised response criteria for malignant lymphoma
Bruce D Cheson et al. J Clin Oncol. 2007.
Abstract
Purpose: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies.
Methods: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations.
Results: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided.
Conclusion: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Similar articles
- New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
Cheson BD. Cheson BD. Radiol Clin North Am. 2008 Mar;46(2):213-23, vii. doi: 10.1016/j.rcl.2008.03.003. Radiol Clin North Am. 2008. PMID: 18619377 - Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Cheson BD, et al. J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800. J Clin Oncol. 2014. PMID: 25113753 Free PMC article. - Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
Delbeke D, Stroobants S, de Kerviler E, Gisselbrecht C, Meignan M, Conti PS. Delbeke D, et al. Oncologist. 2009;14 Suppl 2:30-40. doi: 10.1634/theoncologist.2009-S2-30. Oncologist. 2009. PMID: 19819922 - [Malignant lymphoma].
Okamoto R. Okamoto R. Gan To Kagaku Ryoho. 2009 Dec;36(13):2532-6. Gan To Kagaku Ryoho. 2009. PMID: 20009452 Japanese.
Cited by
- Treatment Outcomes and Prognostic Factors of Chemotherapy Combined With Radiation Therapy for Patients With Early-Stage Extranodal Natural Killer/T-Cell Lymphoma.
Wang SB, Chen JY, Zhao WL, Xu C, Cao WG, Han YM, Cheng S, Xu PP, Zhong HJ, Cai G. Wang SB, et al. Adv Radiat Oncol. 2024 Sep 28;9(12):101647. doi: 10.1016/j.adro.2024.101647. eCollection 2024 Dec. Adv Radiat Oncol. 2024. PMID: 39502091 Free PMC article. - Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Marchi E, O'Connor OA. Marchi E, et al. Ther Adv Hematol. 2012 Aug;3(4):227-35. doi: 10.1177/2040620712445330. Ther Adv Hematol. 2012. PMID: 23606933 Free PMC article. - Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. Wilson WH, et al. Nat Med. 2015 Aug;21(8):922-6. doi: 10.1038/nm.3884. Epub 2015 Jul 20. Nat Med. 2015. PMID: 26193343 Free PMC article. Clinical Trial. - Anthracycline-containing regimens for treatment of follicular lymphoma in adults.
Itchaki G, Gafter-Gvili A, Lahav M, Vidal L, Raanani P, Shpilberg O, Paul M. Itchaki G, et al. Cochrane Database Syst Rev. 2013 Jul 7;2013(7):CD008909. doi: 10.1002/14651858.CD008909.pub2. Cochrane Database Syst Rev. 2013. PMID: 23832787 Free PMC article. Review. - DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
Wang X, Hu J, Dong M, Ding M, Zhu L, Wu J, Sun Z, Li X, Zhang L, Li L, Wang X, Fu X, Wang G, Chen Q, Zhang M, Zhang X. Wang X, et al. Clin Transl Sci. 2021 Jan;14(1):405-411. doi: 10.1111/cts.12893. Epub 2020 Oct 12. Clin Transl Sci. 2021. PMID: 33045134 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical